Pineapple Financial Inc. - Common Shares, no par value (PAPL)

CUSIP: 72303K405

Q4 2025 13F Holders as of 31 Dec 2025

Security type / class
Equity / Common Shares, no par value
Total 13F shares
146,155
Total 13F value
$206,066
Holder snapshot 6 signals
Share change
+8,497
SEC-reported price per share
$1.41
Number of holders
6
Value change
+$11,968
Number of buys
3
Number of sells
1
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
25,994,553

Security key

72303K405

Report period

Q4 2025

Institutions

6

Top holders

6

PAPL full security history Ownership snapshot Full 13F holder table Newer quarter: Q1 2026 Previous quarter: Q3 2025 Pineapple Financial Inc. SEC filings Pineapple Financial Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of PAPL - Pineapple Financial Inc. - Common Shares, no par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Injective Foundation
Disclosed value leader
Injective Foundation
Comparable rows
7/14
Latest evidence
30 Dec 2025
13D/G 3/4/5 13F Lead comparable stake: 37% 7 rows are not safely comparable across share classes. 13D/G row: Injective Foundation Showing 1-6 of 14 holder rows.

Quick read

Injective Foundation leads the comparable SEC ownership view at 37%.

7 of 14 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Injective Foundation's linked filing trail.
Comparable ownership Top 5
Injective Foundation 37%
Kendall Leo Marin 10%
Polar Asset Management Partners Inc. 0.51%
Steward Partners Investment Advis... 0.02%
TD Waterhouse Canada Inc. 0.01%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 14 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Injective Foundation
13D/G 3/4/5
10%+ Owner
13D/G 3/4/5
37%
$26,346,155
9,615,385 shares
 $0 30 Dec 2025
Kendall Leo Marin
3/4/5 13D/G
COO, Director, 10%+ Owner · Marin Kendall Leo
3/4/5 13D/G
10%
from 13D/G
$238,209
2,414,736 shares
mixed-class rows
 — 16 Jul 2025
Polar Asset Management Partners Inc.
13F
Company
13F
0.51%
$499,996
131,578 shares
 — 30 Sep 2025
Steward Partners Investment Advisory, LLC
13F
Company
13F
0.02%
$23,832
4,233 shares
 — 30 Sep 2025
TD Waterhouse Canada Inc.
13F
Company
13F
0.01%
$7,478
1,305 shares
 — 30 Sep 2025
MORGAN STANLEY
13F
Company
13F
0%
$3,035
539 shares
 — 30 Sep 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
6
Shares
146,155
Rows available
6
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders
5
Q4 2025 holders
6
Holder diff
1
Investor Q3 2025 Shares Q4 2025 Shares Share Diff Share Chg % Q3 2025 value Q4 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .